Yahoo · Sep 30, 2026
Why Did CAPR Stock Jump 20% After-Hours Today?
Patients switching from placebo to Deramiocel recorded 76% slower upper-limb decline and 66% slower decline in elbow-related function.
NASDAQ · CAPR
Capricor Therapeutics, Inc.
Healthcare · Biotechnology
$8.95
Up+$0.01 (+0.11%)
Updated Oct 4, 2026, 5:53 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.24B
- P/E ratio
- -17.75
- Dividend yield
- 0.00%
- 52-week range
- $2.96 – $40.37
- Volume
- 2.64M
- Avg. volume
- 2.79M
Price performance · CAPR
CAPR price history
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
CAPR closed at $8.95 after 19 trading sessions, down 1.21% for the selected period.
- Last close
- $8.95
- Period change
- -1.21%
- Period low
- $8.30
- Period high
- $9.47
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $9.14 | $9.24 | $8.7704 | $8.95 | 2.64M |
| Oct 1, 2026 | $9.36 | $9.3945 | $8.83 | $8.94 | 3.88M |
| Sep 30, 2026 | $10.03 | $10.72 | $9.40 | $9.47 | 20.57M |
| Sep 29, 2026 | $8.745 | $8.9699 | $8.50 | $8.57 | 2.67M |
| Sep 28, 2026 | $8.29 | $8.8399 | $8.1517 | $8.71 | 2.1M |
| Sep 25, 2026 | $8.61 | $8.67 | $8.30 | $8.36 | 1.92M |
| Sep 24, 2026 | $8.60 | $8.865 | $8.27 | $8.57 | 2.4M |
| Sep 23, 2026 | $9.26 | $9.36 | $8.52 | $8.67 | 3.15M |
| Sep 22, 2026 | $9.01 | $9.48 | $8.89 | $9.34 | 2.5M |
| Sep 21, 2026 | $9.14 | $9.275 | $8.84 | $8.90 | 2.42M |
| Sep 18, 2026 | $9.295 | $9.3586 | $8.96 | $9.06 | 3.26M |
| Sep 17, 2026 | $8.93 | $9.79 | $8.82 | $9.42 | 3.94M |
| Sep 16, 2026 | $8.58 | $9.07 | $8.41 | $8.56 | 2.39M |
| Sep 15, 2026 | $8.83 | $8.90 | $8.375 | $8.56 | 2.17M |
| Sep 14, 2026 | $9.105 | $9.24 | $8.71 | $8.81 | 2.91M |
| Sep 11, 2026 | $8.32 | $8.67 | $8.26 | $8.37 | 2.07M |
| Sep 10, 2026 | $8.575 | $8.70 | $8.1815 | $8.30 | 2.92M |
| Sep 9, 2026 | $9.08 | $9.27 | $8.60 | $8.64 | 2.75M |
| Sep 8, 2026 | $9.15 | $9.4876 | $8.81 | $9.06 | 2.73M |
Latest CAPR news
The latest Smart Investors Daily articles mentioning CAPR.
Stock researchCompany · Overview
Company
Market Activity
Research & News
CAPR research
Overview
Company profile and research snapshot.
Company profile
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $45.00
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | B. Riley Securities | Buy | — |
| Sep 1, 2026 | Piper Sandler | Overweight | — |
| Aug 14, 2026 | Cantor Fitzgerald | Overweight | — |
| Jul 31, 2026 | Jones Trading | Hold | — |
| Jul 30, 2026 | Piper Sandler | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 23, 2026
Capricor Therapeutics (CAPR) Stock Gets Fair Value Boost After Deramiocel Analyst Revisions
Capricor Therapeutics is back in focus after fresh analyst work led to sharply revised price targets, with some models now pointing to fair value estimates as high as US$27.00 from US$4.38. These shifts reflect a wide spread in analyst opinion as investors weigh the extended FDA action date for deramiocel, the mixed advisory committee outcome, and new upper limb function data that some research views as important. Read on to see what is driving the competing narratives around Capricor...
Yahoo · Sep 17, 2026
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Compan
Benzinga · Sep 14, 2026
B. Riley Securities Upgrades Capricor Therapeutics to Buy, Raises Price Target to $21
B. Riley Securities analyst Madison El-Saadi upgrades Capricor Therapeutics (NASDAQ:CAPR) from Neutral to Buy and raises the price target from $5 to $21.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
